MARKET

FENC

FENC

Fennec Pharmaceuticals Inc
NASDAQ
6.09
-0.41
-6.31%
After Hours: 6.09 0 0.00% 16:36 03/31 EDT
OPEN
6.38
PREV CLOSE
6.50
HIGH
6.48
LOW
6.06
VOLUME
112.76K
TURNOVER
--
52 WEEK HIGH
11.29
52 WEEK LOW
3.960
MARKET CAP
166.21M
P/E (TTM)
-380.6250
1D
5D
1M
3M
1Y
5Y
1D
Fennec Pharmaceuticals Achieves Strong Growth and Expands Market Reach in 2024
TipRanks · 4d ago
FENNEC PHARMACEUTICALS INC. 2024 FORM 10-K ANNUAL REPORT
Press release · 4d ago
Weekly Report: what happened at FENC last week (0317-0321)?
Weekly Report · 03/24 10:06
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last?
NASDAQ · 03/21 14:21
Weekly Report: what happened at FENC last week (0310-0314)?
Weekly Report · 03/17 10:12
Fennec Pharmaceuticals Price Target Maintained With a $13.00/Share by HC Wainwright & Co.
Dow Jones · 03/11 11:02
HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $13 Price Target
Benzinga · 03/11 10:52
Fennec Pharmaceuticals Reports Strong 2024 Sales Growth
TipRanks · 03/11 03:59
More
About FENC
More
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Recently
Symbol
Price
%Change

Webull offers Fennec Pharmaceuticals Inc stock information, including NASDAQ: FENC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FENC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FENC stock methods without spending real money on the virtual paper trading platform.